Holen Sie sich die Stockscreener-App
812.27
4.60%
35.73
Handel nachbörslich:
808.61
-3.66
-0.45%
Schlusskurs vom Vortag:
$776.54
Offen:
$786.18
24-Stunden-Volumen:
1.26M
Relative Volume:
1.27
Marktkapitalisierung:
$85.37B
Einnahmen:
$14.25B
Nettoeinkommen (Verlust:
$4.58B
KGV:
19.45
EPS:
41.7701
Netto-Cashflow:
$3.88B
1W Leistung:
+5.23%
1M Leistung:
+13.07%
6M Leistung:
+50.95%
1J Leistung:
+11.22%
1-Tages-Spanne:
$780.10
$814.10
1-Wochen-Bereich:
$753.20
$814.10
52-Wochen-Spanne:
$476.49
$814.10
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Vergleichen Sie REGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Eingeleitet | HSBC Securities | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-14 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Herabstufung | Argus | Buy → Hold |
| 2025-05-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Regeneron Just Moved From Underperform To BuyHere's Why - Benzinga
Regeneron Stock Lagged Behind the S&P 500 Last Year. Why It’s a Buy Anyway. - Barron's
Regeneron upgraded at BoA on Eylea HD, Dupixent, and pipeline - Seeking Alpha
Regeneron Science Talent Search: 33 Long Island students named semifinalists - Newsday
Regeneron Pharmaceuticals upgraded by Bank of America on improving fundamentals, 2026 catalysts - Proactive financial news
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? - Finviz
Regeneron Pharma gains as BofA upgrades rating - TradingView — Track All Markets
Why Regeneron (REGN) Stock Is Trading Up Today - Finviz
Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 12-Month High After Analyst Upgrade - MarketBeat
Regeneron Pharmaceuticals stock hits 52-week high at $795.88 By Investing.com - Investing.com India
Regeneron Pharmaceuticals stock hits 52-week high at $795.88 - Investing.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Bank of America - MarketBeat
This Lowe's Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Analyst Upgrade: Regeneron Pharmaceuticals (REGN) Rating Boosted to Buy | REGN Stock News - GuruFocus
21 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know - Benzinga
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Robeco Institutional Asset Management B.V. - MarketBeat
Merit Financial Group LLC Has $1.05 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Diabetic Macular Edema Market to hit US$ 7.44 Billion by 2033 | Top - openPR.com
Will Regeneron Pharmaceuticals Inc. stock maintain dividend yield2026 world cup usa national team round of 32 key players low block defense group prediction preview - Улправда
The Truth About Regeneron Pharm: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS
Looking at the Latest Short Interest Trends for Regeneron Pharmaceuticals Inc - Bitget
Peering Into Regeneron Pharmaceuticals Inc's Recent Short Interest - Benzinga
How Dupixent’s New Pediatric Asthma Nod in Japan Will Impact Regeneron Pharmaceuticals (REGN) Investors - simplywall.st
Regeneron Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth - TradingView — Track All Markets
The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson - The Globe and Mail
Regeneron Pharmaceuticals Inc RGO Stock Analysis and ForecastStock Screening Results & Big Gains Low Budget - earlytimes.in
Intellia Stock Declines Around 55% in 3 Months: Here's Why - TradingView — Track All Markets
Regeneron Pharmaceuticals Inc Stock Analysis and ForecastAnalyst Downgrades & Small Budget Capital Gains - earlytimes.in
Allspring Global Investments Holdings LLC Sells 6,253 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Momentum - simplywall.st
Regeneron Shares Maintain Momentum as Key Catalysts Align - AD HOC NEWS
Financiere des Professionnels Fonds d investissement inc. Acquires Shares of 3,171 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Who Owns Regeneron Pharmaceuticals? Top Shareholders and Recent Insider Trades - TIKR.com
Brookwood Investment Group LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results - MSN
Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week - MSN
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026 - The Manila Times
Regeneron Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on January 30, 2026 - Quiver Quantitative
In Case You Missed It: Trial Updates, FDA Approvals & Rejections - Citeline News & Insights
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? - Finviz
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MSN
Generate Investment Management Ltd Acquires 6,778 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
3 Reasons to Avoid REGN and 1 Stock to Buy Instead - FinancialContent
Simplify Asset Management Inc. Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Rockland IDA votes to terminate and recapture Regeneron incentives - Westfair Communications
J&J Bispecific For Atopic Dermatitis Fails To Pass Muster - Citeline News & Insights
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
TB Alternative Assets Ltd. Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bellecapital International Ltd. Buys 2,276 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Cwm LLC Has $30.03 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):